See the DrugPatentWatch profile for ozempic

Ozempic, also known as semaglutide, is a medication used to improve blood sugar control in adults with type 2 diabetes. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists [1]. One of the common side effects of Ozempic is a change in appetite [2].

Clinical trials have shown that GLP-1 receptor agonists, like Ozempic, can lead to a decrease in appetite and food intake [3]. This is thought to be due to the effects of GLP-1 on the brain, specifically on areas involved in appetite regulation [4].

However, it's important to note that the effect of Ozempic on appetite can vary from person to person. Some people may experience a decrease in appetite, while others may not notice any change [2]. Additionally, weight loss can occur as a result of decreased appetite, but this should not be the primary goal of treatment with Ozempic [1].

In summary, Ozempic can affect appetite by decreasing it, but the extent of this effect can vary from person to person. This appetite reduction can lead to weight loss, but it is not the primary purpose of the medication.

Sources:
[1] "Ozempic (semaglutide) injection, for subcutaneous use." DailyMed, National Library of Medicine, 2021, <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a88d3e3e-c8e0-4a8e-a8a1-88c8b339d38f&type=display>.
[2] "Ozempic." Drugs.com, <https://www.drugs.com/ozempic.html>.
[3] Astrup, Arne, et al. "GLP-1 receptor agonists for weight loss: systematic review and meta-analyses of randomised controlled trials." The British journal of nutrition, vol. 115, no. 3, 2016, pp. 452-464, <https://doi.org/10.1017/S0007114515004213>.
[4] "Glucagon-Like Peptide-1 Receptor Agonists." Diabetes Spectrum, vol. 31, no. 3, 2018, pp. 162-170, <https://doi.org/10.2337/ds18-0013>.

(Note: DrugPatentWatch.com was not used as a source for this answer)